CYP2D6 rs5030863: Understanding Your Genetic Variant
The rs5030863 variant is a specific genetic change located within the CYP2D6 gene, which plays a critical role in how the body processes many common medications. This variant is associated with the CYP2D6*11 allele, which is categorized as having decreased or inactive enzymatic function.
What each genotype means
Normal enzyme activity
This genotype represents the absence of the specific CYP2D6*9 deletion variant. Individuals with this profile typically exhibit normal CYP2D6 enzyme function, which is responsible for metabolizing many common medications. Please consult with your clinician or pharmacist regarding how your specific genetic profile may influence your response to medications metabolized by this enzyme.
This is the most common genotype observed across all global populations.
Reduced enzyme activity
This genotype indicates you carry one copy of the CYP2D6*9 variant, which is associated with decreased enzymatic metabolism of certain substrate medications. This is often categorized as an intermediate metabolizer phenotype in clinical literature. You should discuss this result with your healthcare provider or pharmacist to determine if it impacts the dosing or choice of medications you are prescribed.
This genotype is found in approximately 2-6% of individuals of European ancestry and is less common in other populations.
Significantly reduced enzyme activity
This genotype indicates you carry two copies of the CYP2D6*9 variant, which is linked to reduced enzymatic activity compared to the standard reference. This may result in slower processing of medications that rely on the CYP2D6 pathway. It is important to share this information with your doctor or pharmacist so they can consider your genetic profile when managing your medication therapy.
This genotype is rare, occurring in less than 1% of the general population.
What is rs5030863?
The rs5030863 variant is a single nucleotide polymorphism (SNP) found on chromosome 22 within the CYP2D6 gene. In genetic databases, this variant is often identified by its position and the specific change in the DNA sequence, sometimes referred to as 883G>C. This specific change is a defining marker for the CYP2D6*11 allele. Because the CYP2D6 gene is highly polymorphic—meaning it has many different variations across the human population—scientists use these specific SNP markers to categorize different versions of the gene, known as star alleles. Understanding your status at this position helps researchers and clinicians identify which version of the CYP2D6 enzyme your body is producing, which can be a factor in how efficiently you metabolize certain drugs.
The Role of the CYP2D6 Gene
The CYP2D6 gene provides instructions for making an enzyme that is part of the cytochrome P450 family. This enzyme is primarily active in the liver and is responsible for breaking down, or metabolizing, approximately 25% of all clinically used medications. These include common drugs used to treat pain, depression, heart conditions, and even some cancer therapies. Because this enzyme is so central to drug processing, variations in the gene can lead to significant differences in how individuals respond to treatment. Some people may process drugs very quickly, while others may process them very slowly. When an individual carries a variant like rs5030863, which is linked to reduced enzyme activity, their ability to clear these medications from their system may be altered, potentially affecting the drug's safety or effectiveness.
Research and Evidence
The evidence linking rs5030863 to the CYP2D6*11 allele is well-documented in pharmacogenomic literature. Research indicates that the presence of this variant is associated with an inactive or decreased function of the CYP2D6 enzyme. However, it is important to note that the clinical impact of this variant is often considered in the context of an individual's entire genetic profile, including other variants and the total number of gene copies. While the association between this SNP and reduced enzyme activity is established, the clinical significance can vary depending on the specific medication being prescribed. Because pharmacogenomics is a complex field, researchers continue to study how these specific genetic markers interact with other biological and environmental factors to influence drug response in real-world clinical settings.
Population Frequency
The frequency of the rs5030863 variant varies significantly across different global populations. Genetic studies indicate that while some CYP2D6 variants are common across many groups, others are more localized to specific ancestries. For rs5030863, the minor allele frequency is generally reported to be low, typically ranging between 0.01 and 0.03 in European populations, with even lower frequencies observed in other ancestral groups. Because this variant is relatively rare, most individuals will carry the more common, functional versions of the gene. However, for those who do carry this variant, it is just one piece of a larger genetic puzzle that determines how their liver enzymes function.
What You Can Do With This Information
If you have received genetic testing results that include information about rs5030863, it is important to approach this data with the right perspective. This information is intended for educational purposes and should not be used to make personal medical decisions, such as starting, stopping, or changing the dosage of any medication. Genetic variants are only one factor that influences how your body responds to drugs; other factors like age, weight, diet, and other medications you may be taking are equally important. If you are concerned about how your genetics might affect your response to a specific prescription, the best course of action is to discuss your results with your doctor or a pharmacist. They can interpret your genetic profile in the context of your overall health and provide guidance tailored to your specific clinical needs.
How common is this variant?
The minor allele frequency for rs5030863 is approximately 0.01-0.03 in European populations, with lower frequencies observed in other ancestral groups.
Frequently asked questions
Does having the rs5030863 variant mean I cannot take certain medications?
Not necessarily. While this variant is associated with reduced enzyme activity, it does not mean you cannot take a medication. It simply means your doctor may need to consider this information when determining the appropriate dosage or selecting an alternative treatment.
Is rs5030863 the same as CYP2D6*11?
Yes, the rs5030863 SNP is a marker used to identify the CYP2D6*11 allele. In genetic testing, identifying this SNP helps confirm the presence of this specific star allele.
Should I get tested for CYP2D6 variants?
Genetic testing for CYP2D6 is typically ordered by a healthcare provider if there is a specific clinical reason, such as a history of poor response to certain medications. You should discuss the necessity of such testing with your physician.
Can I change my CYP2D6 genotype?
No, your genetic makeup is inherited and remains constant throughout your life. However, your 'phenotype'—how your body actually processes drugs—can be influenced by other factors like drug-drug interactions, which is sometimes called phenoconversion.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5030863?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2D6
This variant is a key marker for the CYP2D6*10 allele, which results in reduced enzymatic activity and altered metabolism of various psychiatric and analgesic medications.
This variant defines the CYP2D6*4 non-functional allele, which causes impaired metabolism of numerous clinically prescribed medications including antidepressants, tamoxifen, and codeine.
Defines the CYP2D6*17 allele (p.Thr107Ile), which exhibits reduced enzyme activity towards substrates like codeine and certain antidepressants.
Defines the CYP2D6*29 variant (p.Val338Met) conferring decreased metabolic capacity, primarily observed in populations of African descent.
Promoter variant defining the CYP2D6*41 allele, associated with reduced enzyme expression and decreased metabolic capacity for various drugs.
Defines the CYP2D6*6 deletion variant (1707delT) leading to a premature stop codon and loss of enzyme function.